All In Biotech

Drug Trial Radar · NCT07309055

A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 201 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

201

Planned (sponsor's estimate)

Start

Mar 21, 2026

Primary completion

Nov 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Dec 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial was designed to evaluate the efficacy and safety of SHR-1819 in adolescents with moderate-to-severe atopic dermatitis.

Conditions

  • Adolescents With Moderate-to-severe Atopic Dermatitis

Interventions

  • SHR-1819 InjectionDrug

    SHR-1819 injection.

  • SHR-1819 Injection PlaceboDrug

    SHR-1819 injection placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with Eczema Area and Severity (EASI)-75.Time frame: At week 16.
  2. Proportion of patients with an Investigator's Global Assessment (IGA) score of either 0 or 1.Time frame: At week 16.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.